Physician profile
Michael Turner
NPI 1003800764
$645.60
in general payments reported to CMS, 2019-2025
12 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $30.06 · 2021: $61.20 · 2023: $77.17 · 2024: $171 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.44 | 2019-2025 | Botox |
| Merck Sharp & Dohme LLC | $74.72 | 2019 | |
| Janssen Biotech, INC. | $55.51 | 2019 | |
| Ucb, INC. | $31.62 | 2025 | Rystiggo |
| Astellas Pharma US INC | $22.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.17 | 2024 | Gvoke Hypopen |
| Antares Pharma, INC. | $17.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.28 | 2020 | |
| Eisai INC. | $15.71 | 2021 | |
| Hospira, INC. | $15.17 | 2021 | |
| Grifols USA, LLC | $12.78 | 2020 | |
| Adamas Pharmaceuticals, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.